Selective Serotonin Reuptake Inhibitors (SSRIs) and Monoamine Oxidase Inhibitors (MAOIs)

Deep Dive

SSRIs and MAOIs both enhance monoaminergic neurotransmission but do so at different control points. SSRIs inhibit the serotonin transporter, inc... SSRIs and MAOIs both enhance monoaminergic neurotransmission but do so at different control points. SSRIs inhibit the serotonin transporter, increasing synaptic serotonin with relative selectivity, which translates to broad efficacy for major depression and multiple anxiety disorders with a comparatively favorable adverse‑effect profile—chiefly gastrointestinal upset, sexual dysfunction, sleep disturbance, hyponatremia in older adults, and, for some agents, QT considerations and bleeding risk when combined with NSAIDs. MAOIs, by irreversibly inhibiting monoamine oxidase A and B, prevent the breakdown of serotonin, norepinephrine, and dopamine, producing robust increases in monoamines. Clinically, this potency can yield benefits in atypical depression and some cases of treatment‑resistant depression; however, it creates a narrow safety margin with diet and drug interactions. The pharmacologic overlap in serotonin enhancement underlies the central safety lesson: do not combine or closely sequence SSRIs and MAOIs. Serotonin syndrome can present rapidly with autonomic instability, neuromuscular hyperactivity (tremor, clonus, hyperreflexia), and altered mental status, and can escalate to hyperthermia and multi‑organ complications. Hypertensive reactions occur when MAOIs interact with dietary tyramine or sympathomimetic agents, producing severe headaches, chest pain, and dangerous blood pressure elevations. Consequently, washout intervals—at least 14 days between most agents, extended to 5 weeks after fluoxetine—are standard, and cross‑tapers are generally avoided. Clinicians prioritize medication reconciliation, education about OTC decongestants and cough suppressants, and strict avoidance of high‑risk combinations such as linezolid, methylene blue, meperidine, tramadol, dextromethorphan, and serotonergic supplements. When an SSRI is ineffective or poorly tolerated, options include switching within class, augmenting with non‑serotonergic strategies, or considering MAOIs under specialist oversight—particularly for atypical features (mood reactivity, hypersomnia, hyperphagia). Adjunctive nonpharmacologic modalities—CBT/IPT, exercise, rTMS, ECT, light therapy, and mindfulness‑based approaches—can improve outcomes without compounding pharmacokinetic risks. Management emphasizes individualized risk assessment, clear patient education on warning signs, and coordinated monitoring of vitals and mental status during any transition.